TY - JOUR T1 - A Diarylheptanoid from Lesser Galangal (<em>Alpinia officinarum</em>) Inhibits Proinflammatory Mediators via Inhibition of Mitogen-Activated Protein Kinase, p44/42, and Transcription Factor Nuclear Factor-κB JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther SP - 925 LP - 931 DO - 10.1124/jpet.103.049171 VL - 305 IS - 3 AU - Prem N. Yadav AU - Zhihua Liu AU - Mohamed M. Rafi Y1 - 2003/06/01 UR - http://jpet.aspetjournals.org/content/305/3/925.abstract N2 - The diarylheptanoid 7-(4′-hydroxy-3′-methoxyphenyl)-1-phenylhept-4-en-3-one (HMP) is a naturally occurring phytochemical found in lesser galangal (Alpinia officinarum). In the present study, we have demonstrated the anti-inflammatory properties of this compound on mouse macrophage cell line (RAW 264.7) and human peripheral blood mononuclear cells (PBMCs) in vitro. Treatment of RAW 264.7 cells with HMP (6.25–25 μM) significantly inhibited lipopolysaccharide (LPS)-stimulated nitric oxide (NO) production. This compound also inhibited the release of LPS-induced proinflammatory cytokines interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) from human PB-MCs in vitro. In addition, Western blotting and reverse transcription-polymerase chain reaction analysis demonstrated that HMP decreased LPS-induced inducible nitric-oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) protein and mRNA expression in RAW 264.7 cells. Furthermore, HMP treatment also reduced nuclear factor-κB (NF-κB) DNA binding induced by LPS in RAW 264.7 cells. To elucidate the molecular mechanism for inhibition of proinflammatory mediators by HMP (25 μM), we have studied the effect of HMP on LPS-induced p38 and p44/42 mitogen-activated protein kinase (MAPK). We observed that the phosphorylation of p44/42 MAPK in LPS-stimulated RAW 264.7 cells was markedly inhibited by HMP, whereas activation of p38 MAPK was not affected. These results suggested that HMP from lesser galangal suppressed the LPS-induced production of NO, IL-1β, and TNF-α and expression of iNOS and COX-2 gene expression by inhibiting NF-κB activation and phosphorylation of p44/42 MAPK. The American Society for Pharmacology and Experimental Therapeutics ER -